Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.

ABSTRACT: Cancer is increasingly prevalent among older adults with geriatric impairments, yet the impact of frailty on immune checkpoint inhibitor (ICI) therapy outcomes remains underexplored. This study aims to assess the association between frailty and grade ≥3 immune-related adverse events (irAEs), clinical benefit, all-cause hospitalization, and mortality in older patients undergoing ICI therapy. Patients aged ≥65 years, treated with anti-PD-1 monotherapy for a solid malignancy (September 2018-February 2024), were prospectively included in this multicenter study. The association between frailty, components of the geriatric assessment, and number of impaired geriatric domains with the occurrence of grade ≥3 irAEs, all-cause hospitalization, and clinical benefit was analyzed using univariable and

SUBMITTER: Ozkan A 

PROVIDER: S-EPMC12765961 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature